Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
NCT07688772 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 11, 2026
- Completion date
- December 31, 2026
- Enrollment
- 196 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
seasonal allergic rhinitis